Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Feb. 19, 2025 — New research focuses on diagnostic delays experienced by people with epilepsy, a neurological disorder characterized by unpredictable seizures that affects over 3 million people ...

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.

Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...

Choose from Epilepsy Awareness stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a ...

Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...